ITIM-dependent negative signaling pathways for the control of cell-mediated xenogeneic immune responses. 2013

Maria-Luisa del Rio, and Jörg D Seebach, and Carlos Fernández-Renedo, and Jose-Ignacio Rodriguez-Barbosa
Transplantation Immunobiology Section, Institute of Biomedicine, University of Leon, Leon, Spain; Leon University Hospital, Castilla and Leon Transplantation Regional Agency, Leon, Spain.

Xenotransplantation is an innovative field of research with the potential to provide us with an alternative source of organs to face the severe shortage of human organ donors. For several reasons, pigs have been chosen as the most suitable source of organs and tissues for transplantation in humans. However, porcine xenografts undergo cellular immune responses representing a major barrier to their acceptance and normal functioning. Innate and adaptive xenogeneic immunity is mediated by both the recognition of xenogeneic tissue antigens and the lack of inhibition due to molecular cross-species incompatibilities of regulatory pathways. Therefore, the delivery of immunoreceptor tyrosine-based inhibitory motif (ITIM)-dependent and related negative signals to control innate (NK cells, macrophages) and adaptive T and B cells might overcome cell-mediated xenogeneic immunity. The proof of this concept has already been achieved in vitro by the transgenic overexpression of human ligands of several inhibitory receptors in porcine cells resulting in their resistance against xenoreactivity. Consequently, several transgenic pigs expressing tissue-specific human ligands of inhibitory coreceptors (HLA-E, CD47) or soluble competitors of costimulation (belatacept) have already been generated. The development of these robust and innovative approaches to modulate human anti-pig cellular immune responses, complementary to conventional immunosuppression, will help to achieve long-term xenograft survival. In this review, we will focus on the current strategies to enhance negative signaling pathways for the regulation of undesirable cell-mediated xenoreactive immune responses.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014181 Transplantation Immunology A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection. Immunology, Transplantation
D014183 Transplantation, Heterologous Transplantation between animals of different species. Xenotransplantation,Heterograft Transplantation,Heterografting,Heterologous Transplantation,Xenograft Transplantation,Xenografting,Transplantation, Heterograft,Transplantation, Xenograft
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D015478 Antigens, Heterophile Antigens stimulating the formation of, or combining with heterophile antibodies. They are cross-reacting antigens found in phylogenetically unrelated species. Antigens, Heterogenetic,Antigens, Xenogeneic,H-D Antigens,Hanganutziu-Deicher Antigen,Hanganutziu-Deicher Antigens,Heteroantigens,Heterologous Antigen,Heterologous Antigens,Heterophile Antigen,Heterophile Antigens,Paul-Bunnell Antigens,Xenoantigen,Xenoantigens,Antigens, Heterologous,Antigens, Heterophil,Antigens, Xenogenic,Heterogenetic Antigens,Antigen, Hanganutziu-Deicher,Antigen, Heterologous,Antigen, Heterophile,Antigens, H-D,Antigens, Hanganutziu-Deicher,Antigens, Paul-Bunnell,H D Antigens,Hanganutziu Deicher Antigen,Hanganutziu Deicher Antigens,Heterophil Antigens,Paul Bunnell Antigens,Xenogeneic Antigens,Xenogenic Antigens

Related Publications

Maria-Luisa del Rio, and Jörg D Seebach, and Carlos Fernández-Renedo, and Jose-Ignacio Rodriguez-Barbosa
January 2020, Methods in molecular biology (Clifton, N.J.),
Maria-Luisa del Rio, and Jörg D Seebach, and Carlos Fernández-Renedo, and Jose-Ignacio Rodriguez-Barbosa
May 2000, Free radical biology & medicine,
Maria-Luisa del Rio, and Jörg D Seebach, and Carlos Fernández-Renedo, and Jose-Ignacio Rodriguez-Barbosa
October 2008, Transplantation proceedings,
Maria-Luisa del Rio, and Jörg D Seebach, and Carlos Fernández-Renedo, and Jose-Ignacio Rodriguez-Barbosa
April 2016, European journal of dermatology : EJD,
Maria-Luisa del Rio, and Jörg D Seebach, and Carlos Fernández-Renedo, and Jose-Ignacio Rodriguez-Barbosa
January 1982, Oncology,
Maria-Luisa del Rio, and Jörg D Seebach, and Carlos Fernández-Renedo, and Jose-Ignacio Rodriguez-Barbosa
November 2023, European journal of immunology,
Maria-Luisa del Rio, and Jörg D Seebach, and Carlos Fernández-Renedo, and Jose-Ignacio Rodriguez-Barbosa
July 2006, The EMBO journal,
Maria-Luisa del Rio, and Jörg D Seebach, and Carlos Fernández-Renedo, and Jose-Ignacio Rodriguez-Barbosa
January 2014, Hypoxia (Auckland, N.Z.),
Maria-Luisa del Rio, and Jörg D Seebach, and Carlos Fernández-Renedo, and Jose-Ignacio Rodriguez-Barbosa
April 2013, Biochemical pharmacology,
Maria-Luisa del Rio, and Jörg D Seebach, and Carlos Fernández-Renedo, and Jose-Ignacio Rodriguez-Barbosa
November 2008, European journal of immunology,
Copied contents to your clipboard!